Saturday, February 20, 2021 4:47:09 PM
The reason I took such a large position in CLWD has to do with the companies fundamentals. Financials are as good as you're going to find in OTC land; a better than most share structure; not only actual revenues but respectable revenue numbers; solid clientele list and above all the specialized features of their "PRODUCT" and the infinite growth prospects of the industry it which it serves.
Now to your question: when it comes to public companies the degree of revenue growth trumps everything. It's quite simple. If you're a company that has significant revenue growth quarter after quarter investor momentum will always keep a share price ascending even through a reverse split. The flip side of course being your typical OTC company that has no viable product or revenues to speak of and only has intent on riding the dilution wave until it's at the point of doing a reverse split and starting the process all over again. Naturally, the reverse split will play out and the share price will plummet.
I anticipate the incorporation of AI into SWARM having a major impact on revenue growth going forward. If this starts playing out over the next couple years I feel the O/S count will still be reasonable enough to where the share price may reach the Nasdaq qualifying standard on its own. Price to sales multiples are really high in today's markets so they're not scrutinized as much when it comes to traditional measurements. Now you have analysts justifying a share price based on revenue numbers 1 to 2 years down the road instead of a couple quarters. Metrics have changed considerably and when you factor in CLWD providing services to trillion dollar industries such a digital advertising/marketing and AI, well you get the picture and its all good.
Recent AIAD News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/01/2024 10:45:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 09:35:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/10/2024 10:50:41 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/10/2024 10:50:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/10/2024 10:49:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/10/2024 10:48:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2023 06:28:38 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 10/20/2023 08:29:14 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/14/2023 08:05:23 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 07/18/2023 09:00:58 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM